Skip to main content
Evidence: C+Anti-InflammatoryGut HealthSkin & Hair

KPV: Benefits, Dosage & FDA Status

α-MSH Tripeptide KPV

The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.

FDA Status

Not FDA-approved — research peptide

Typical Dose

200–500 mcg orally or topical (research only)

Evidence Grade

C+Preclinical evidence + anecdotal clinical use

Half-Life

Minutes

Routes of Administration

oral, topical, subcutaneous

First Synthesized

1980s

Clinics Indexed

26 providers have offered KPV in our tracked directory.

Mechanism of Action

Tripeptide fragment of α-MSH that downregulates NF-κB signaling and pro-inflammatory cytokines.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.

Reported Side Effects

  • Generally well-tolerated

Contraindications

  • Pregnancy

Commonly Stacked With

Regulatory & Safety Context

FDA status: Not FDA-approved — research peptide

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on KPV. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 18404148

Last reviewed: 2026-04-30

← Back to all peptides